Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and Indomethacin in Castration-Resistant Prostate Cancer
NCT02935205Phase 2Recruiting
- Start
- Jan 2017
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of indomethacin in castration-resistant prostate cancer (CRPC). Started Jan 2017; status: recruiting.
02
Drugs
indomethacin
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02935205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935205.